Lakshman 2018 2/20/20 smoldering myeloma risk: one point each for BMPC >20%, serum M-protein >2 g/dL, and involved/uninvolved FLC ratio >20 (strict greater-than). 0 factors low (median TTP 110 months), 1 intermediate (68), 2 or 3 high (29). Not Mayo 70/20, not PETHEMA, not myeloma ISS, not a treatment order. BMPC 10-59 and FLC 0.01-99.9 (IMWG 2014 SLiM myeloma is rejected). magent does not assay marrow, M-protein, or free light chains.
| Network | Scheme | Amount | Pay To |
|---|---|---|---|
| Base | exact | $0.005000 USDC | 0x836B...9Ee2 |